Genetic prognostic markers in colorectal cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 50, Issue 6, 1997, Pages 281-288

  Houlston, R S ^a   Tomlinson, I P M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Colorectal cancer; Prognosis

Indexed keywords

PROTEIN P53;

CANCER GENETICS; COLON CARCINOGENESIS; COLORECTAL CANCER; HUMAN; ONCOGENE K RAS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031443375     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.50.6.281     Document Type: Review

References (134)

1. HMSO. Cancer statistics. Registrations. England and Wales. London: HMSO, 1989.
2. HMSO. Mortality statistics. Cause. England and Wales. London: HMSO, 1992.
3. Finlay IG, Pickford IR. Colorectal carcinoma. In: Lawson DH, ed. Current medicine, 4th edn. Edinburgh: Churchill Livingstone, 1994:51-64.
4. Beart RW, Steele GJ, Menck HR, Chmiel JS, Ocwieja KE, Winchester DP. Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer. J Am Coll Surg 1995;181: 225-36.
5. Dukes CE, Bussey HJR. The spread of cancer and its effect on prognosis. Cancer 1958;12:309-20.
6. Jass JR, Love SB, Northover JMA. A new prognostic classification of rectal cancer. Lancet 1987;ii:1303-6.
7. Finlay IG, Meck D, Bruton F, et al. Growth rate of hepatic metastases in colorectal cancer. Br J Surg 1988;75:641-4.
8. Morson B, Dawson I, Day D, Jass J, Price A, Williams G. Morson and Dawson's gastrointestinal pathology, 3rd edn. Oxford: Blackwell Scientific Publications, 1990.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
10. Powell SM, Zilz N, Beazer Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-7.
11. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
12. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253: 661-5.
13. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-33.
14. Solomon E, Voss R, Hall V, et al. Chromosome 5 allele loss in human colorectal carcinomas. Nature 1987;328:616-9.
15. Miyaki M, Konishsi M, Kikuchi Yanoshita R, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumours. Cancer Res 1994;54:3011-20.
16. Joslyn G, Richardson DS, White R, Alber T. Dimer formation by an N terminal coiled coil in the APC protein. Proc Natl Acad Sci USA 1993;90:11109-13.
17. Baeg GH, Matsumine A, Kuroda T, et al. The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase. EMBO J 1995;14:5618-25.
18. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262: 1734-7.
19. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta catenin. Science 1993;262:1731-4.
20. Browne S, Williams A, Hague A, Butt A, Paraskeva C. Loss of apc protein expressed by human colonic epithelial cells and the appearance of a specific low molecular weight form is associated with apoptosis in vitro. Int J Cancer 1994;59:56-54.
21. Burchill SA. The tumour suppressor APC product is associated with cell adhesion. Bioessays 1994;16:225-7.
22. Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 1994;54:3676-81.
23. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
24. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non polyposis colon cancer. Nat Genet 1993;5:279-82.
25. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
26. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-16.
27. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995;9:48-55.
28. Tomlinson IPM, Novelli MR, Bodmer WF. The mutation rate and cancer. Proc Natl Acad Sci USA 1996;93:14800-3.
29. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994;35:1419-23.
30. Ilyas M, Tomlinson IPM. Genetic pathways in colorectal cancer. Histopathology 1996;28:389-99.
31. Redston M, Papadopoulos N, Caldas C, Kinzler K, Kern S. Common occurrence of APC and K ras mutation in the spectrum of colitis associated neoplasias. Gastroenterology 1995;108:383-92.
32. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55:2035-8.
33. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-78.
34. Tops CM, van der Klift HM, van der Luijt RB, et al. Non allelic heterogeneity of familial adenomatous polyposis. Am J Med Genet 1993;47:563-7.
35. Whitelaw SC, Murday VA, Tomlinson IPM, et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 1997;112:327-34.
36. Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist AM, et al. Localization of a susceptibility locus for Peutz Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997;15:87-90.
37. Jacoby RF, Schlack S, Cole CE, Marshall DJ, Kuhlman G, et al. Identification of a juvenile polyposis tumor suppressor gene locus (JP1) and demonstration of its deletion in sub epithelial cells [abstract]. Gastroenterology 1996;110:A535.
38. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
39. Jeevarathnam P, Cottier DS, Browett PJ, Vanderwater NS, Pokos V, Jass JR. Familial giant hyperplastic polyposis predisposing to colorectal cancer a new hereditary bowel cancer syndrome. J Pathol 1996;179:20-5.
40. Shepherd JA. Regression phenomenon in familial polyposis. Proc R Soc Med 1972;65:169.
41. Giardello FM. Sulindac and polyp regression. Cancer Metastasis Rev 1994;13:279-83.
42. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
43. Smith AJ, Stern HS, Penner M, et al. Somatic APC and K ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
44. Minamoto T, Yamashita N, Ochiai A, et al. Mutant K ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 1995;75(suppl 6):1520-6.
45. Pretlow TP. Aberrant crypt foci and K ras mutations: earliest recognised players or innocent bystanders in colon carcinogenesis? Gastroenterology 1995;108:600-3.
46. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
47. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
48. Vogelstein BV, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumour development. N Engl J Med 1988;319:525-32.
49. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991;251:1366-70.
50. Curtis LJ, Bubb VJ, Gledhill S, Morris RG, Bird CC, Wyllie AH. Loss of heterozygosity of MCC is not associated with mutation of the retained allele in sporadic colorectal cancer. Hum Mol Genet 1994;3:443-6.
51. Hahn SA, Hoque AT, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996;56:490-4.
52. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
53. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205.
54. Carder P, Wyllie AH, Purdie CA, et al. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 1993;8:1397-401.
55. Krawczak M, Smith SB, Schmidtke J, Kakkar VV, Cooper DN, Hovig E. Somatic spectrum of cancer associated single basepair substitutions in the p53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat 1995;5:48-57.
56. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717-22.
57. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80.
58. Kawasaki Y, Monden T, Morimoto H, et al. Immunohistochemical study of p53 expression in microwave fixed, paraffin embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97:244-9.
59. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3,8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
60. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-9.
61. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
62. Gonzalez ZM, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
63. Leister I, Weith A, Bruderlein S, et al. Human colorectal cancer: high frequency of deletions at chromosome 1p35. Cancer Res 1990;50:7232-5.
64. Praml C, Finke LH, Herfarth C, Schlag P, Schwab M, Amler L. Deletion mapping defines different regions in 1p34.2 pter that may harbor genetic information related to human colorectal cancer. Oncogene 1995;11:1357-62.
65. Wildrick D, Alfaro S, Gope R, Boman B. A study of chromosome 6 allele loss in human colorectal carcinomas. Anticancer Res 1992;12:1717-19.
66. Fujiwara Y, Emi M, Ohata H, et al. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 1993;53:1172-4.
67. Cunningham C, Dunlop MG, Wyllie AH, Bird CC. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene 1993;8:1391-6.
68. Young J, Leggett B, Ward M, et al. Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas. Oncogene 1993;8:671-5.
69. Yana I, Kurahashi H, Nakamori S, et al. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers. Int J Cancer 1995;60:174-7.
70. Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non polyposis colorectal cancer patients. Nat Med 1996;2:169-74.
71. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
72. Young J, Leggett B, Gustafson C, et al. Genomic instability occurs in colorectal carcinomas but not in adenomas. Hum Mutat 1993;2:351-4.
73. Ilyas M, Tomlinson IPM, Novelli MR, Hanby A, Bodmer WF, Talbot IC. Clinico pathological features and p53 expression in left sided sporadic colorectal cancers with and without microsatellite instability. J Pathol 1996;179: 370-5.
74. da Costa LT, Liu B, El Deiry WS, Hamilton SR, Vogelstein B, Markowitz S, et al. Polymerase and variants in RER colorectal tumours. Nat Genet 1995;9:10-1.
75. Linn SC, Giaccone G. MDR1/P glycoprotein expression in colorectal cancer. Eur J Cancer 1995;31A:1291-4.
76. Nuovo GJ. In situ PCR: protocols and applications. PCR Methods Appl 1995;4:S151-67.
77. Pignatelli M, Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E cadherin and beta 1 integrins in colorectal tumour cells. Br J Cancer 1992;66:629-34.
78. De Bruin PAF, Griffioen G, Verspaget HW, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988;48:4520-4.
79. Sier CFM, Vloedgraven HJM, Griffioen G, et al. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. Br J Cancer 1995;71:393-6.
80. MacDonald NJ, de la Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995;31A:1096-100.
81. Martinez JA, Prevot S, Nordlinger B, et al. Overexpression of nm23 H1 and nm23 H2 genes in colorectal carcinomas and loss of nm23 H1 expression in advanced tumour stages. Gut 1995;37:712-20.
82. Iacopetta B, DiGrandi S, Dix B, Haig C, Soong R, House A. Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. Eur J Cancer 1994;30A:664-70.
83. Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 1994;70:813-18.
84. Campo E, Miquel R, Jares P, et al. Prognostic significance of the loss of heterozygosity of nm23 h1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-21.
85. Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. Pathobiology 1994;62:172-9.
86. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-11.
87. Gerdes H, Chen Q, Elahi AH, Sircar A, Goldberg E, Winawer D, et al. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Anticancer Res 1995;15:13-24.
88. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer Gastroenterology 1992;102: 1136-41.
89. Cohn KH, Ornstein DL, Wang F, LaPaix FD, Phipps K, Edelsberg C, et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5 year follow up study. Cancer 1997;79:233-44.
90. Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y, et al. Allelic loss in colorectal carcinoma. JAMA 1989;261:3099-103.
91. Khine K, Smith DR, Goh HS. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer 1994;73:28-35.
92. Purdie CA, Piris J, Bird CC, Wyllie AH. 17q allele loss is associated with lymph node metastasis in locally aggressive human colorectal cancer. J Pathol 1995;175:297-302.
93. Kelemen PR, Yaremko ML, Kim AH, Montag A, Michelassi F, Westbrook CA. Loss of heterozygosity in 8p is associated with microinvasion in colorectal carcinoma. Genes Chromosomes Cancer 1994;11:195-8.
94. Gustafson CE, Young J, Leggett B, Searle J, Chenevix-Trench G. Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours. Br J Cancer 1994;70: 395-7.
95. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K ras 2 mutation type. Cancer 1993;71:3827-38.
96. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J. Type and number of Ki ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994;54:3376-8.
97. Span M, Moerkerk PT, De Goeij AF, Arends JW. A detailed analysis of K ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996;69:241-5.
98. Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC. K ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995;130:9-14.
99. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
100. Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker, Swalsky PA, et al. Prognostic value of p53 and K ras 2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
101. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c Ha ras1 genes mutated at codon 12. Nature 1984;312:71-5.
102. Bos JL, Toksoz D, Marshall CJ, Verlaan de Vries M, Veeneman GH, van der Eb AJ, et al. Amino acid substitutions at codon 13 of the N ras oncogene in human acute myeloid leukaemia. Nature 1985;315:726-30.
103. Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M. Analysis of the transforming potential of the human H ras gene by random mutagenesis. Proc Natl Acad Sci USA 1984;81:4008-12.
104. Manne Y, Bekesi E, Kung HF. Ha ras proteins exhibit GTPase activity: point mutations that activate Ha ras gene products result in decreased GTPase activity. Proc Natl Acad Sci USA 1985;82:376-80.
105. Der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986;44:167-76.
106. McGrath JP, Capon DJ, Goeddel DV, Levinson AD. Comparative biochemical properties of normal and activated human ras p21 protein. Nature 1984;310:644-9.
107. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32.
108. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1 associated hereditary cancer. Gastroenterology 1996;110:682-7.
109. Fujita S, Moriya Y, Sugihara K, Akasu T, Ushio K. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn J Clin Oncol 1996;26:351-5.
110. Ishimaru G, Adachi J, Shiseki M, Yamaguchi N, Muto T, Yokota J. Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer 1995;64:153-7.
111. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al. Microsatellile instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-9.
112. Remvikos Y, Tominaga O, Hammel P, Laurent Puig P, Salmon RJ, Dutrillauix B, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
113. Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996;16:951-7.
114. Diez M, Enriquez JM, Camunas J, Gonzalez A, Gutierrez A, Muguerza JM, et al. Prediction of recurrence in B C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 1995;21:635-9.
115. Grewal H, Guillem JG, Klimstra DS, Cohen AM. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum 1995;38:1176-81.
116. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K. Prognostic significance of p53 and c erbB 2 immunohistochemical evaluation in coloreclal adenocarcinoma. Histol Histopathol 1995;3:661-8.
117. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-41.
118. Tomoda H, Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 1995;58: 125-8.
119. Morrin M, Kelly M, Barrett N, Delaney P. Mutations of Ki ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994;35:1627-31.
120. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node positive colorectal cancer patients. J Clin Oncol 1994;12:2043-50.
121. Tanaka M, Omura K, Watanabe Y, Oda V, Nakanishi I. Prognostic factors of colorectal cancer: K ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 1994;57:57-64.
122. Suzuki H, Matsumoto K, Koide A, Tada T, Fujino I, Okuda A, et al. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma. Surg Today 1994;24:85-7.
123. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37-527-34.
124. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c Ki ras gene mutations in colorectal cancer. Gastroenterology 1993;104: 57-64.
125. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, et al. Expression of p53 protein in colorectal cancer and its relationship to short term prognosis. Cancer 1992;70:2778-84.
126. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55: 5217-21.
127. Hamelin R, Laurent Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106:42-8.
128. Bertorelle R, Esposito G, Del Misiro A, Belluco C, Nitti D, Lise M, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995;19:463-71.
129. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995;11:647-52.
130. Goh HS, Chan CS, Khine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994;344:233-4.
131. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-8.
132. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23.
133. Steeg PS, Abrams JS. Cancer prognostics: past, present and p27. Nat Med 1997;3:152-4.
134. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome dependent degradation of the cyclin dependandent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.